TTRX

8.0956.31%
MD

Martin Dewhurst

Independent Director

Mr. Martin Dewhurst serves as an Independent Director since September 8, 2026 at NovaBridge Biosciences. He has several years' senior advisory and operational experience across biopharma, medical devices and consumer health, shaped by his work in North America, Europe, Asia and the Middle East/South Africa. He serves as Operating Partner at Revival Healthcare Capital LLC since April 2026. He joined the firm in 2023. At Revival Healthcare Capital LLC, he also served as Operating Advisor from 2023 to April 2026. He focuses on Private Debt. He serves as Director of Distalmotion SA, Director of Cytovation ASA since February 2025 and Independent Director of Turn Therapeutics Inc. since January 7, 2026. He also serves on the board of Unilabs. Additionally, he is Senior Advisor of Lightrock LLP and a senior advisor to PJT Partners. He served as Chairman of the Advisory Board of MedGenome Inc. from November 2023. Prior to joining Revival Healthcare Capital LLC, Mr. Dewhurst was with McKinsey & Company for several years, where he held several leadership roles. From 2014 to 2021, he led the firm’s global life sciences practice. He also co-founded and co-led the McKinsey Health Institute and led McKinsey’s cross-industry organization practice in EMEA. Mr. Dewhurst earned an M.B.A. in Management with Dean’s List distinction from INSEAD and a B.A. from the University of Oxford.

Positions